- Phase 3 Trial Start: Expected in Q1 2027 for larazotide acetate, the first potential FDA-approved therapeutic for celiac disease.
- Trial Design: 414 participants will undergo a 500mg gluten challenge to test larazotide's protective mechanism.
- Market Need: No FDA-approved treatments exist for the ~1 in 100 people worldwide with celiac disease.
Experts view Interlude Biopharma's Phase 3 trial as a high-stakes but scientifically rigorous attempt to validate larazotide's novel upstream prevention approach, with potential to redefine celiac disease treatment if successful.
Rethinking Celiac Disease: Larazotide's High-Stakes Phase 3 Comeback
MELBOURNE, Australia – November 19, 2026 – In the high-attrition world of biopharmaceutical development, second acts are rare. Third acts are nearly unprecedented. Yet, as the 21st International Celiac Disease Symposium (ICDS) convenes in Melbourne this week, the industry is witnessing the improbable resurrection of a drug that has passed through the hands of multiple defunct corporate entities over two decades.
Interlude Biopharma Co., a newly launched, late-stage drug development company, has announced FDA clearance for an Investigational New Drug (IND) application to initiate a Phase 3 clinical trial for larazotide acetate. Expected to begin in the first quarter of 2027, the trial aims to establish the first FDA-approved therapeutic intervention for celiac disease. But beyond the standard corporate optimism lies a fascinating pivot in regulatory strategy, a high-stakes clinical trial design, and a deeply personal origin story that underscores the hidden costs of autoimmune disease.
From Bankruptcy to Breakthrough: The Human Element
To understand the significance of Interlude’s announcement, one must trace the turbulent lineage of its lead asset. Larazotide acetate is an oral, locally acting peptide originally developed in the 2000s by Alba Therapeutics. It later transitioned to Innovate Biopharmaceuticals, which merged to become 9 Meters Biopharma. In 2022, 9 Meters halted a Phase 3 trial of the drug—not due to safety concerns, but because the statistical feasibility of proving symptom reduction in a standard "real-world" trial design proved insurmountable. By July 2023, 9 Meters Biopharma had filed for Chapter 7 bankruptcy, effectively leaving the intellectual property to be liquidated and the drug’s promise seemingly extinguished.
Enter Mark Paresky, co-founder and executive chairman of Interlude Biopharma. Paresky’s acquisition of the liquidated asset was not driven solely by a market opportunity, but by a forensic understanding of the daily, compounding toll the disease takes on patients.
"When my young daughter was diagnosed with celiac disease, our family saw firsthand how it affected her health and became a daily burden for all of us, from school lunches and birthday parties to restaurant meals and travel," Paresky stated. "Even with a strict gluten-free diet, accidental exposure is a constant concern."
Paresky’s search for solutions led him to Dr. Alessio Fasano, a pediatric gastroenterologist and the pioneering researcher who discovered zonulin—the protein that regulates intestinal tight junctions. Recognizing that larazotide’s mechanism of action was fundamentally sound despite its previous corporate mishandling, Paresky acquired the program. The formation of Interlude represents a calculated gamble to answer whether this sidelined molecule can finally cross the regulatory finish line.
Shifting the Paradigm: Upstream Prevention
The historical failure of celiac drug development largely stems from flawed endpoints. Traditional trials have attempted to treat patients in "real-life" settings after the immune system is already activated by gluten exposure. Once the inflammatory cascade begins, dampening the resulting symptoms is notoriously difficult to measure and achieve.
Interlude’s strategy, developed in consultation with the FDA, abandons the reactive model in favor of proactive mucosal protection. Larazotide acetate is designed to act as a zonulin inhibitor. By regulating the intestinal tight junctions—the gatekeepers of the gut barrier—the drug aims to prevent gluten fragments from crossing into the lamina propria in the first place.
Dr. Fasano, now serving as a scientific advisor to Interlude, explained the biological rationale. "In celiac disease, gluten exposure triggers a cascade of events, including functional disruption of the gut barrier, translocation of gluten peptides from the gut lumen into the lamina propria, and the subsequent triggering of an immune response leading to the classic celiac enteropathy in genetically predisposed individuals," Fasano noted. "Following the FDA's recommendation, Interlude's Phase 3 trial is designed to evaluate whether larazotide acetate can help prevent intestinal damage caused by gluten exposure, rather than simply treating symptoms after they occur."
This upstream mechanism is crucial. By shifting the clinical endpoint from subjective symptom reduction to the objective preservation of intestinal architecture during a controlled challenge, Interlude is testing a regulatory paradigm that could redefine how we approach chronic inflammatory diseases characterized by barrier dysfunction.
The High-Stakes 500mg Gluten Challenge
The scientific elegance of upstream prevention brings with it a formidable clinical hurdle. To prove the drug protects the gut, Interlude must intentionally expose trial participants to the very substance that damages it.
The trial, aiming to enroll approximately 414 adolescents and adults across 100 U.S. sites, will utilize a rigorous gluten challenge. Following a run-in period, participants will receive a study bar containing 500 milligrams of gluten for 12 weeks. This dosage is meticulously calculated to represent the upper range of estimated real-world inadvertent exposure. Participants will be randomized to receive either 0.25 mg or 0.5 mg of larazotide acetate, or a placebo, three times daily.
Subjecting individuals with biopsy-confirmed celiac disease to a prolonged gluten challenge raises complex ethical and safety considerations. Intentional exposure can cause severe discomfort and mucosal damage. However, the trial's design reflects a carefully negotiated balance between patient safety and the demand for unequivocal efficacy data.
One independent regulatory consultant familiar with gastroenterology trials noted that the FDA’s willingness to clear this protocol signals a maturation in the agency's understanding of celiac pathology. "You cannot prove a shield works without throwing stones at it," the consultant observed. "By standardizing the gluten exposure to 500 milligrams, the trial eliminates the variable of unpredictable real-world diets that doomed previous Phase 3 attempts. It is a high-stakes approach, but statistically, it is the most viable path to approval."
Larazotide’s robust safety profile in prior Phase 2b trials—where it met its primary endpoint in a 342-patient study without severe adverse events—provides the ethical foundation for this aggressive challenge design.
Market Realities and the Road Ahead
As Interlude prepares for its Q1 2027 launch, the macro-market implications are significant. Currently, there are no FDA-approved treatments for the estimated one in 100 people worldwide living with celiac disease. The only standard of care is a lifelong, strict gluten-free diet—a regimen fraught with hidden costs, from exorbitant food prices to the psychological burden of hyper-vigilance.
"As we prepare to begin the Phase 3 study, we are working with clinical sites and speaking with celiac disease patient organizations about how we can collaborate," Paresky added. "We are grateful for the chance to try to do more for families living with this disease."
The success of larazotide acetate would do more than offer an adjunct therapy for accidental gluten exposure; it would clinically validate the zonulin pathway. If tight junction regulation can successfully defend the intestinal barrier against gluten, the mechanism could theoretically be applied to a vast array of autoimmune and chronic inflammatory conditions where barrier dysfunction is a root cause.
For investors and industry watchers, Interlude Biopharma represents a masterclass in forensic asset recovery. By aligning a neglected molecule with a modernized, FDA-backed trial design and a highly motivated leadership team, the company has transformed a bankrupt liability into one of the most closely watched clinical programs of the decade. Whether larazotide can finally deliver on its decades-long promise remains to be seen, but the architecture of its comeback is a testament to the resilience of both science and the patients waiting for it.
Topics & Related
Drug Development
Biotechnology
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →